Vehicle Service Group to Expand Manufacturing Capacity in Madison, Indiana
Get Alerts DOV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
Revenue Growth %: +6.3%
Join SI Premium – FREE
New automated production line will bring jobs, skills development, and enhance local manufacturing capabilities
The new production line is designed to complement VSG's existing manufacturing capabilities and ensure the company can serve the North American market efficiently and reliably. An over
"This strategic expansion is part of VSG's global manufacturing optimization strategy to invest in automation, new technologies, and improved quality along with workforce development in our key markets," said
The project timeline includes equipment installation, hiring, and training of team members, with production ramp-up planned for Q1 2026.
VSG has been a long-standing employer in the
For more information about VSG and its manufacturing operations, please visit www.vsgdover.com.
About Vehicle Service Group:
Vehicle Service Group (VSG), part of Dover Corporation, is a global leader in vehicle service and repair equipment. Through its trusted brands like Rotary, Forward, Direct Lift and Chief Collision Technology, VSG delivers innovation, quality, and performance to automotive service professionals around the world.
About Dover:
Dover is a diversified global manufacturer and solutions provider with annual revenue of over
Vehicle Service Group Contact:
(812) 265-9543
[email protected]
Dover Media Contact:
Adrian Sakowicz, VP, Communications
(630) 743-5039
[email protected]
Dover Investor Contact:
(630) 743-2566
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/vehicle-service-group-to-expand-manufacturing-capacity-in-madison-indiana-302463547.html
SOURCE Dover
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Systech Launches TraceIQ, Helping Transform Pharmaceutical Traceability from Compliance to Operational Intelligence
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- FMI Releases 2026 Compensation Trends Study
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share